Influence of anticoagulant therapy on platelet mRNA profiling

Influence of anticoagulant therapy on platelet mRNA profiling - Influence of anticoagulation on platelet mRNA profiling

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON50253

Enrollment

Registered

2020-08-19

Start date

2017-09-12

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atrial fibrillation venous thromboembolism

Interventions

anticoagulant therapy

platelet mRNA profiling

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: - Age 18 years or older - Objectively confirmed, new onset atrial fibrillation or acute VTE (deep vein thrombosis or pulmonary embolism)

Exclusion criteria

Exclusion criteria: - Anticoagulant therapy at the time of the first blood withdrawal - Inability for blood withdrawal; - Inability or refusal to provide written informed consent

Design outcomes

Primary

Measure	Time frame
Correlation between the platelet mRNA profile, expressed as mean log2-transformed counts per million, before anticoagulation and during anticoagulation.	—

Secondary

Measure	Time frame
Differences in plasma levels of coagulation markers before and during anticoagulation, including D-dimer and endogenous thrombin potential.	—

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)